The adaptive immune system is a complex network of cells that protect the body from invasion by foreign pathogens. Crucial to the function of the adaptive immune system is the activation, proliferation and differentiation of T cells in response to foreign pathogen presentation by antigen presenting cells. T cell activation is driven through different signaling pathways that are dependent on phosphorylation of substrates by kinases. In the PLC pathway that activates the il2 gene program, Protein Kinase C-q (PKCq) and Notch1 localize to the immunological synapse and help drive the signaling cascade that leads to robust T cell activation. It has been previously shown that PKCq and Notch1, both interact with the CBM complex at the immunological synapse. Additionally, PKCq and Notch1 both have specific cytoplasmic and nuclear functions that help drive the il2 gene program. Here, we demonstrate the localization of PKCq and Notch1 constructs transfected into HEK 293 cells. The use of deletion constructs of Notch1 was intended to inform us of what functional domain of Notch1 was responsible for the interaction with PKCq, however no direct interaction was demonstrated with the PKCq and Notch1 constructs used in these experiments. We hypothesize that this is likely due to the inactive form of PKCq found in our construct, or a result of the cell type used in these experiments.

We sought to evaluate the individual contributions of Notch1 and PKC-ζ to disease progression in a mouse model of immune-mediated bone marrow failure and to define a mechanism for their potential cellular cooperation. We transferred parental bulk splenocytes into F1-hybrid recipients to induce a robust immune-mediated bone marrow failure (BMF) that we could partially rescue by administering a pharmacological inhibitor of Notch activation. Transferring splenocytes from PKC--ζ-/- animals did not induce disease, and treating animals with a pharmacological inhibitor of PKC-ζ also provided full protection from disease. We found that inhibiting Notch1 resulted in PKC-ζ down-regulation, and blocking PKC-ζ reduced Notch1 activation, possibly within a positive feedback loop. Our data suggest that both Notch1 and PKC-ζ contribute to disease progression in our mouse model of immune-mediated bone marrow failure. Furthermore, additional findings from the lab demonstrated physical interactions between Notch1, members of the T cell signalosome and PKC-ζ that are essential to mediating full activation of T cells following signaling through the TCR and CD28. Notch1 and/or PKC-ζ may represent novel therapeutic targets in the treatment of bone marrow failure.

Fra-1 appartient à la famille des facteurs de transcription AP-1. Son expression est particulièrement élevée dans les cellules de cancer du sein qui n'expriment pas le récepteur aux œstrogènes (RE-), c'est-à-dire les cellules les plus agressives. L'inhibition de Fra-1 dans ces cellules entraîne une diminution de la motilité, de l'invasion et de la prolifération, mais elle entraîne aussi de profonds changements de morphologie. Les cellules RE-, qui présentent un phénotype mésenchymateux s'arrondissent et établissent un plus grand nombre de contacts cellule-cellule après l'inhibition de Fra-1. Dans les cellules RE-, la β-caténine est localisée au noyau ou dans le cytoplasme, ce qui est un marqueur de mauvais pronostic. Au cours de cette thèse, j'ai montré que Fra-1 régule la localisation nucléaire de la β-caténine et ainsi régule son activité transcriptionelle en agissant très tardivement sur la voie Wnt. J'ai également mis en évidence une interaction physique directe entre Fra-1 et la β-caténine qui pourrait être responsable de cet effet. De plus, l'analyse de microarrays par RT-QPCR a révélé la régulation d'autres gènes comme la mœsine, la fibronectine et l'extracellular matrix protein 1, qui pourraient également jouer un rôle dans la régulation de l'agressivité tumorale par Fra-1. Par ailleurs, Fra-1 est une protéine instable et nous avons montré qu'elle est phosphorylée et stabilisée par PKCθ. Fra-1 est d'ailleurs nécessaire à l'effet de la kinase sur la motilité cellulaire. / Fra-1 is a member of the AP-1 transcription factor family. It is aberrantly expressed in breast cancer cells lacking Estrogen Receptor (ER-) expression, which are the most aggressive ones. Fra-1 inhibition in these cells leads to a decreased in motility, invasion and proliferation, but also to deep morphologic changes. ER- cells, which present a mesenchymal phenotype, become rounder and establish a greater number of cell-cell contacts after Fra-1 inhibition. In ER- cells, β-catenin is nuclear or cytoplasmic, which is considering as a poor prognosis marker. During this PhD, I demonstrate that Fra-1, which acts very downstream in the Wnt/β-catenin signaling pathway, regulates the nuclear localization of β-catenin leading to up-regulation transcriptional activity of β-catenin. I also found that Fra-1 directly interacts with β-catenin. In addition, RT-QPCR microarrays analysis has revealed the regulation of other genes such as mœsin, fibronectin and extracellular matrix protein 1, which might also take part in the tumoral aggressiveness regulated by Fra-1. Moreover, we show that Fra-1, which is an unstable protein, is phosphorylated and stabilized by PKCθ. Furthermore, Fra-1 is necessary to mediate the kinase effect on cell motility.

The prevalence of obesity, which is considered as a disease, has been increasing uncontrollably over the last two decades. Obesity is a state of disregulated energy homeostasis characterized by hypothalamic resistance to adiposity signals (insulin and leptin). While many factors are involved in the development of obesity, excess dietary fat has been proposed as one of the main causal factors. This causes disrupted energy homeostasis by inducing both leptin and insulin resistance in the central nervous system. Although brain tissue was considered to be insulin independent for a long time, insulin is now recognized to have important functions in the brain in the regulation of feeding behavior, energy expenditure and peripheral metabolism to maintain energy homeostasis. Recently, our lab discovered that insulin has an anorectic effect when it is applied into the central nucleus of the amygdala (CeA), a response that is similar to its effect when it is intracerebroventricularly (icv) administered into the hypothalamus. Our lab also demonstrated that rats fed a high fat diet lost the anorectic response to CeA insulin and became insulin resistant. These data suggested that insulin signaling in the amygdala had an important role in controlling food intake and energy expenditure in similar ways to the hypothalamus. It also suggests that a high fat diet inhibits amygdala insulin signaling in the CeA. Both in vitro cell culture and in vivo animal studies have been used to investigate the effects of dietary fats on insulin signaling in neuronal cells and in the amygdala. Using both hypothalamic GT1-7 cells and primary amygdala cells in culture, the saturated fatty acid palmitic acid was shown to inhibit insulin signaling (Akt phosphorylation). This response appears to be related to the activation of PKC-θ since the inhibitory effect of palmitic acid on Akt phosphorylation was greater in GT1-7 cells transfected with PKC-θ compared to wild type cells and was abolished in GT1-7 cells transfected with PKC-θ siRNA. Further investigations in vivo confirmed that insulin stimulated Akt and mTOR signaling in the CeA of rats and that the insulin stimulation of Akt phosphorylation, but not mTOR phosphorylation, was inhibited in rats fed a high fat diet for 3 days or by infusing palmitic acid into the CeA for 3 days. These experiments also identified that fatty acid and insulin signaling in the CeA differentially affected Akt and mTOR signaling in the hypothalamus and suggest that these neural connections might be important components of the neural pathways through which insulin in the amygdala affects food intake and peripheral metabolism. This research has provided novel insight into the effects of dietary fats on insulin signaling in an area of the brain, the CeA, that is now recognized to have effects on energy balance and peripheral metabolism.